Last updated: February 27, 2026
What is the drug associated with NDC 62756-0746?
NDC 62756-0746 refers to Remdesivir, marketed as Veklury. It is an antiviral medication developed by Gilead Sciences, primarily used for treating COVID-19.
Market Overview
Product Status and Approval Timeline
- Initial FDA approval: October 22, 2020, for hospitalized COVID-19 patients.
- Expanded indications: May 2021, including treatment of hospitalized severe COVID-19 cases.
- Global reach: Approved in over 60 countries, including the European Union, Japan, and Canada.
Manufacturing and Supply
- Gilead ensures regular supply through multiple manufacturing facilities.
- Distribution channels include hospitals, specialty pharmacies, and infusion centers.
Competitive Landscape
- Primary competitors: Pfizer’s Paxlovid and Merck’s Lagevrio.
- Remdesivir remains the earliest approved antiviral, with current demand driven by ongoing COVID-19 cases.
Market Demand Dynamics
Current Market Size
- North America covers 70% of global remdesivir sales, driven by COVID-19 hospitalization rates and reimbursement infrastructure.
- In 2022, anticipated sales exceeded $5 billion globally.
Usage Trends
- Peak utilization occurred during the surge periods of COVID-19 variants.
- Steady decline expected as vaccination rates increase and alternative therapies emerge.
Price Point Considerations
- Pricing in the US: List price per 100 mg vial is approximately $520.
- Reimbursement: Medicaid and Medicare negotiations influence final prices; prices can vary between $390 to $520 per vial depending on negotiated discounts and healthcare setting.
Price Projections and Future Outlook
| Year |
Estimated Global Sales (USD) |
Key Factors |
| 2023 |
$4.2 billion |
Continuing COVID-19 management, stockpiling, and expanded access |
| 2024 |
$2.8 billion |
Decline driven by vaccine coverage, newer antiviral options |
| 2025 |
$1.5 billion |
Transition to maintenance and outpatient therapy, focus on specific populations |
Influencing Factors
- Epidemiological trends: Variants and vaccination rates influence COVID-19 case severity and treatment need.
- Regulatory decisions: Potential extensions or restrictions on approval impact market access.
- Pricing and reimbursement: Payer negotiations and government policies strongly impact average selling prices.
Potential Market Shifts
- Introduction of oral antiviral treatments (e.g., Paxlovid) will reduce inpatient demand.
- Expanded use in outpatient settings and prophylactic use could sustain or increase demand, albeit at lower prices.
- Patent expiration or licensing agreements could alter pricing structures.
Regulatory and Reimbursement Factors
- In the US, Medicare and Medicaid adjust coverage policies annually.
- International markets display diverse reimbursement policies, affecting net prices.
- Gilead has entered low-income country agreements to improve access, impacting overall revenue.
Risks and Opportunities
Risks
- Emergence of new variants less susceptible to remdesivir.
- Competition from new antiviral agents with superior efficacy profiles.
- Reduced COVID-19 case counts impacting clinical use.
Opportunities
- Potential expansion into prophylaxis or outpatient management.
- Combination therapies increasing utilization scope.
- Strategic partnerships to access emerging markets.
Key Takeaways
- NDC 62756-0746 (Remdesivir) commands a significant market share in COVID-19 therapeutics.
- The market is driven by pandemic trends, with demand expected to decline over time.
- US pricing remains around $520 per vial; global prices are lower, depending on negotiations and subsidies.
- Revenue projections indicate a declining trend, influenced by vaccine-driven mitigation and competition.
- Opportunities exist in outpatient and prophylactic applications, but regulatory and market dynamics introduce risks.
FAQs
1. What factors determine remdesivir's future market share?
Genetic variations in COVID-19, vaccine coverage, emerging therapies, and regulatory approvals influence usage and market share.
2. How does the pricing of remdesivir compare globally?
US prices hover around $520 per vial, while European and Asian prices are generally lower, often negotiated on a country-by-country basis or through volume discounts.
3. Will remdesivir retain exclusivity, and how does that affect pricing?
Gilead holds patents until at least 2030 in key markets. Patent extensions or licensing can influence future pricing and access.
4. What are the main competitive threats to remdesivir?
Oral antivirals like Paxlovid and Lagevrio, which offer easier administration and comparable or superior efficacy, threaten market position.
5. How might COVID-19 treatment guidelines impact the demand for remdesivir?
Shifts towards outpatient management, oral therapies, or updated treatment protocols favor or diminish remdesivir use depending on clinical evidence and regulatory recommendations.
References
[1] Gilead Sciences. (2022). Veklury (Remdesivir) Prescribing Information.
[2] U.S. Food and Drug Administration. (2020). FDA Approves First Treatment for COVID-19.
[3] IQVIA. (2022). Global Viral Disease Market Report.
[4] European Medicines Agency. (2021). Veklury Marketing Authorization.
[5] McKinsey & Company. (2022). COVID-19 Therapeutics Market Outlook.
